Pipeline and approval signals
Search agency notices, approvals, recalls, and regulatory updates from global authorities.
60 of 1,114 tracked regulatory updates from 40 agencies and publishers, page 1 of 2.
Clinical trials for medicines: Inclusion and Diversity Plan pilot findings publishedMHRA UKDecision: Orphan registered medicinal productsMHRA UKGuidance: Herbal medicines granted a traditional herbal registration (THR)MHRA UKMHRA launches patient safety essay competition for MedSafetyWeekMHRA UKTriheptanoin (Dojolvi) approved to treat adults and children with a group of rare inherited disordersMHRA UKMHRA Safety Roundup: October 2026MHRA UKMHRA approves gene-editing treatment for children aged five and over with serious inherited blood disordersMHRA UKClass 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydrochloride 10mg Film-Coated Tablets, EL(26)A/45MHRA UKClass 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40 mg/mL solution for injection in pre-filled syringe, EL(26)A/44MHRA UKField Safety Notices: 19 to 23 October 2026MHRA UKAccess, new active substance and biosimilar work sharing initiativesMHRA UKDecision: Medical devices given exceptional use authorisationsMHRA UKTransparency data: MHRA Performance DataMHRA UKNew MHRA research puts needle-free Strep A vaccine within reachMHRA UK#MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and appMHRA UKClass 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43MHRA UKMHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adultsMHRA UKMHRA approves new oral treatment for moderate to severe plaque psoriasisMHRA UKGuidance: COVID-19 test validation approved productsMHRA UKOpportunities for patients and the public to be involved in the work of the MHRAMHRA UKGovernment confirms indefinite recognition of CE marked medical devicesMHRA UKMedical devices regulations: targeted consultation on the indefinite recognition of CE marked devicesMHRA UKDecision: Parallel import licences granted in 2026MHRA UKDecision: Marketing authorisations granted in 2026MHRA UKIXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety reviewMHRA UKMHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndromeMHRA UKUK regulator brings new AI and MedTech agenda to AdvaMedMHRA UKField Safety Notices: 5 to 9 October 2026MHRA UKField Safety Notices: 12 to 16 October 2026MHRA UKConsultation on schools holding Adrenaline Nasal Sprays for anaphylaxisMHRA UKMHRA consults on proposals to allow schools to keep spare adrenaline nasal sprays on siteMHRA UKNova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013MHRA UKField Safety Notices: 27 to 31 January 2025MHRA UKRegister medical devices to place on the marketMHRA UKCounterfeit weight loss pens worth £2 million seized by MHRA and West Midlands PoliceMHRA UKDecision: Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredientsMHRA UKMHRA introduces new safeguards to strengthen antidepressant safety information following major reviewMHRA UKAntidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunctionMHRA UKResearch: Antidepressants – updated safety communicationsMHRA UKSafety Public Assessment ReportsMHRA UKGuidance: Antidepressants: use and safetyMHRA UKGood laboratory practice (GLP) for safety tests on chemicalsMHRA UKGuidance: MHRA Strategy to 2030: What it means for youMHRA UKMHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicinesMHRA UKCorporate report: MHRA Strategy 2030MHRA UKMedicines: apply for a variation to your marketing authorisationMHRA UKMHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetesMHRA UKContinuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014MHRA UKClass 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42MHRA UKField Safety Notices for October 2026MHRA UK